20854-58-4Relevant academic research and scientific papers
Suzuki-Miyaura coupling of aryl sulfonates with arylboronic acids using a morpholine-Pd(OAc)2 catalyst system
Abe, Taichi,Mino, Takashi,Watanabe, Kohei,Yagishita, Fumitoshi,Sakamoto, Masami
, p. 3909 - 3916 (2014/06/24)
We report a new catalyst system, a morpholine-Pd(OAc)2 complex, for Suzuki-Miyaura coupling of aryl tosylates or mesylates with arylboronic acids to give biaryl compounds. The morpholine-Pd(OAc)2 catalyst system is proposed to be a precursor of the catalytically active species in the coupling reaction. Aryl chlorides and aryl triflates can also be used in this coupling reaction. Altogether, 22 biaryl compounds were obtained using this catalyst system. We report a new catalyst system, a morpholine-Pd(OAc) 2 complex, for Suzuki-Miyaura coupling of aryl tosylates or mesylates with arylboronic acids to give biaryl compounds. The morpholine-Pd(OAc) 2 catalyst system is proposed to be a precursor of the catalytically active species in the coupling reaction. Copyright
Synthesis and biological evaluation of spiro-δ-lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2)
Xu, Kuiying,Wetzel, Marie,Hartmann, Rolf W.,Marchais-Oberwinkler, Sandrine
experimental part, p. 406 - 421 (2012/06/18)
17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyzes the oxidation of the potent estradiol (E2) to the less active estrogen estrone (E1). Inhibitors of this enzyme should maintain the local level of E2 in bone tissue when the E2 concentration in t
Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design
Allan, Gillian M.,Vicker, Nigel,Lawrence, Harshani R.,Tutill, Helena J.,Day, Joanna M.,Huchet, Marion,Ferrandis, Eric,Reed, Michael J.,Purohit, Atul,Potter, Barry V.L.
, p. 4438 - 4456 (2008/09/21)
The 17β-hydroxysteroid dehydrogenases (17β-HSDs) catalyze the interconversion between the oxidized and reduced forms of androgens and estrogens at the 17 position. The 17β-HSD type 1 enzyme (17β-HSD1) catalyzes the reduction of estrone (E1) to estradiol a
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: Novel CYP17 inhibitors for the treatment of prostate cancer
Pinto-Bazurco Mendieta, Mariano A. E.,Negri, Matthias,Jagusch, Carsten,Müller-Vieira, Ursula,Lauterbach, Thomas,Hartmann, Rolf W.
supporting information; experimental part, p. 5009 - 5018 (2009/07/04)
Abiraterone, a steroidal cytochrome P450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. Since steroidal compounds often show side
6-Aryl-8H-indeno[1,2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency
Chordia, Mahendra D.,Zigler, Molly,Murphree, Lauren J.,Figler, Heidi,Macdonald, Timothy L.,Olsson, Ray A.,Linden, Joel
, p. 5131 - 5139 (2007/10/03)
Allosteric enhancers (AEs) of the A1 adenosine receptor (A 1AR) have potential as drugs for treating neurological, cardiovascular, and renal diseases. This report describes the synthesis and evaluation of a series of 6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines that exhibited AE activity at the A1AR. Palladium-mediated condensation of arylboronic acids with 5-bromoindan-1-one generated arylindanones 2a-aj for iodine-catalyzed condensation with thiourea, generating 2-aminothiazolium salts 3a-aj. Binding studies using membranes from cells stably expressing human A 1ARs, A2AARs, or A3ARs evaluated AE activity and receptor subtype selectivity. The EC50 of the AE activities of compounds 3m-o, 3x, and 3ae were 2.2, 1.5, 0.9, 1.0, and 3.0 μM, respectively, substantially lower than that of the well characterized 2-amino-3-aroylthiophene (PD 81,723), >10 μM. The new compounds also have substantially higher maximal AE activity. These compounds had no AE activity at the A2AAR and only minimal activity at the A3AR. 2005 American Chemical Society.
Novel imidazolyl and triazolyl substituted biphenyl compounds: Synthesis and evaluation as nonsteroidal inhibitors of human 17α-Hydroxylase-C17, 20-lyase (P450 17)
Zhuang, Yan,Wachall, Bertil G.,Hartmann, Rolf W.
, p. 1245 - 1252 (2007/10/03)
The synthesis of a new series of P450 17 inhibitors is described. The imidazol-1-yl compounds 5 showed strong inhibition of P450 17 rat and especially human enzyme, the most active compounds being 5ax, 5ay and 5bx with IC50 values of 0.17, 0.24 and 0.25 μM, respectively (ketoconazole: 0.74 μM). The 1,2,4-triazol-1-yl compounds 6 were less active, while the 1,2,4-triazol-4-yl compounds 7 were inactive. The title compounds showed little inhibition of P450 arom. The most active P450 17 inhibitors 5ax and 5ay markedly decreased the testosterone plasma concentration of SD rats 2 h after application of 0.019 mmol/kg. After 6 h, 5ay still exhibited a strong effect. Copyright (C) 2000 Elsevier Science Ltd.
